Patents by Inventor Vincent Brichard

Vincent Brichard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion protein
    Patent number: 8309096
    Abstract: Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: November 13, 2012
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Normand Blais, Martine Boyer, Vincent Brichard, Jamila Louahed, Denis Martin, Remi Palmantier, Clement Rioux
  • Method
    Publication number: 20110070268
    Abstract: Methods for characterisation of patients as responders or non-responders to therapy based on differential expression of one or more genes are provided. Gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and new diagnostic kits and methods of treatment are also provided. The kits and methods relate to the treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from MAGE expressing tumours.
    Type: Application
    Filed: September 17, 2010
    Publication date: March 24, 2011
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Vincent Brichard, Benjamin Georges Elie Lea Ghislain Dizier, Olivier Gruselle, Jamila Louahed, Fernando Ulloa-Montoya
  • Fusion Protein
    Publication number: 20100029912
    Abstract: Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells.
    Type: Application
    Filed: July 15, 2009
    Publication date: February 4, 2010
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Normand Blais, Martine Boyer, Vincent Brichard, Jamila Louahed, Denis Martin, Remi Palmantier, Clement Rioux
  • Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy
    Publication number: 20100021424
    Abstract: The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles and new diagnostic kits and methods. The invention further relates to treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from Mage expressing tumours.
    Type: Application
    Filed: May 31, 2007
    Publication date: January 28, 2010
    Inventors: Vincent Brichard, James Scott Clark, Thierry Coche, Swann Romain Jean-Thomas Gaulis, Olivier Gruselle, Frederic Lehmann, Jamila Louahed
  • Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of Cancer
    Publication number: 20100008980
    Abstract: A combination therapy comprising an immunotherapy based on a tumour antigen or an immunological derivative thereof, and at least one other treatment for cancer such as chemotherapy, radiotherapy and/or surgery.
    Type: Application
    Filed: January 8, 2008
    Publication date: January 14, 2010
    Inventors: Vincent Brichard, Catherine Marie Ghislaine Gerard, Frederic Francois Eugene Lahmann, Jamila Louahed
  • METHOD OF TREATING MAGE POSITIVE CANCER
    Publication number: 20090186049
    Abstract: The present invention relates to methods for treating a range of cancers, for example MAGE positive cancers, including, but not limited to melanoma and non-small cell lung cancer (NSCLC). The present invention relates to methods for treating cancer in the adjuvant (eg. post-operative) setting and the active disease setting.
    Type: Application
    Filed: May 24, 2007
    Publication date: July 23, 2009
    Inventors: Vincent Brichard, Frederic Eugene Lehmann
  • Mage-3 and NY-ESO-1 Based Polyvalent Vaccine for Cancer Immunotherapy
    Publication number: 20070243196
    Abstract: The present invention provides novel vaccine formulations for the treatment of cancer antigens. The vaccine comprises a modified MAGE-3 antigen, a NY-ESO-1 antigen, and an adjuvant comprising a saponin and a immunostimulatory oligonucleotide.
    Type: Application
    Filed: May 2, 2005
    Publication date: October 18, 2007
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Claudine Bruck, Vincent Brichard, Remi Palmantier, Melinda Meaders
  • METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS
    Patent number: 6669946
    Abstract: The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: December 30, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethe
  • Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals
    Publication number: 20020128200
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Application
    Filed: December 11, 2001
    Publication date: September 12, 2002
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel, Bernard Lethe
  • Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals
    Patent number: 6284476
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: October 11, 1995
    Date of Patent: September 4, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethé
  • Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors
    Patent number: 6201111
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or ‘TRAP”, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: March 13, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wölfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
  • Brain glycogen phosphorylase cancer antigen
    Patent number: 6096520
    Abstract: The invention describes brain glycogen phosphorylase tumor rejection antigen precursors, including nucleic acids encoding such tumor rejection antigen precursors, tumor rejection antigen peptides or precursors thereof and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a brain glycogen phosphorylase tumor rejection antigen or precursor thereof.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: August 1, 2000
    Assignees: Ludwig Institute for Cancer Research, The Regents of the University of California
    Inventors: Vincent Brichard, Aline van Pel, Thierry Boon-Falleur, Fredric A. Gorin
  • Precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 6001975
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: December 14, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Methods for determining expression of NAG tumor rejection antigen precursor
    Patent number: 5958711
    Abstract: New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: October 23, 1998
    Date of Patent: September 28, 1999
    Assignee: Inserm (Institute National De La Sante Et De La Recherche Medicale
    Inventors: Yannick Guilloux, Francine Jotereau, Thierry Boon-Falleur, Sophie Lucas, Vincent Brichard
  • Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
    Patent number: 5886145
    Abstract: New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: August 21, 1997
    Date of Patent: March 23, 1999
    Assignee: INSERM (Institute National de la Sante et de la Rechereche Medicale)
    Inventors: Yannick Guilloux, Francine Jotereau, Thierry Boon-Falleur, Sophie Lucas, Vincent Brichard
  • Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5856091
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 10, 1995
    Date of Patent: January 5, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
  • Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5854203
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: December 29, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5843687
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: October 19, 1995
    Date of Patent: December 1, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur
  • Isolated tyrosinase derived peptides and uses thereof
    Patent number: 5843688
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: December 1, 1998
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur, Etienne DePlaen, Pierre Coulie, Jean-Christophe Renauld, Bernard Lethe
  • Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
    Patent number: 5837476
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: November 17, 1998
    Assignee: Ludwig Institute
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen